Literature DB >> 2439518

Phospholipid and arachidonic acid metabolism in zymosan-stimulated human monocytes: modulation by cAMP.

R W Godfrey, R M Manzi, D E Gennaro, S T Hoffstein.   

Abstract

Receptor-ligand interaction in mononuclear phagocytes is intimately linked to alterations in membrane phospholipids and release of arachidonic acid (AA). In addition, synthesis of bioactive lipids from released AA can result in further modification of cell responses. Upon challenge with opsonized zymosan, [3H]-arachidonic acid ([3H]-AA)-labeled human monocytes released 25 +/- 2% of their incorporated radiolabel within 30 min. Pretreatment of the monocytes with 5 X 10(-4) M isobutylmethylxanthine (IBMX) or 1 X 10(-3) M dibutyryl cyclic AMP (d-cAMP) inhibited total [3H]-AA release in the presence of zymosan by 47% and 42%, respectively. Analysis of incorporated [3H]-AA in cellular phospholipid pools indicated that significant amounts of label were lost from both phosphatidylcholine (PC) and phosphatidylinositol (PI) during zymosan stimulation. Treatment with d-cAMP substantially inhibited the loss of label from PC, but had no affect on PI. HPLC analysis of cell supernatants from zymosan-treated cells indicated that 5-HETE was the predominant metabolite generated from [3H]-AA, and its production was depressed during treatment with d-cAMP. Phospholipase activity in human monocyte homogenates was not effected by d-cAMP or IBMX at the highest concentrations used, whether these were added directly to the homogenate or by pretreatment of whole cells, demonstrating that inhibition required an intact cell. These results suggest that human monocytes exposed to opsonized zymosan release AA via two mechanisms and that modulation by cAMP is indirectly effecting a phospholipase directed towards PC.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2439518     DOI: 10.1002/jcp.1041310310

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  5 in total

Review 1.  Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.

Authors:  T J Torphy; B J Undem
Journal:  Thorax       Date:  1991-07       Impact factor: 9.139

2.  Interactions between cyclic AMP stimulating drugs and PAF-acether in guinea-pig alveolar macrophages.

Authors:  M Bachelet; M J Adolfs; J Masliah; G Bereziat; B B Vargaftig; I L Bonta
Journal:  Agents Actions       Date:  1989-01

3.  Cyclic adenosine monophosphate and diacylglycerol. Mutually inhibitory second messengers in cultured rat inner medullary collecting duct cells.

Authors:  I Teitelbaum
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

4.  The effect of cyclic AMP and cyclic GMP phosphodiesterase inhibitors on the superoxide burst of guinea-pig peritoneal macrophages.

Authors:  N C Turner; L J Wood; F M Burns; T Gueremy; J E Souness
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

5.  Inhibition of allergen-induced lung eosinophilia by type-III and combined type III- and IV-selective phosphodiesterase inhibitors in brown-Norway rats.

Authors:  W Elwood; J Sun; P J Barnes; M A Giembycz; K F Chung
Journal:  Inflamm Res       Date:  1995-02       Impact factor: 4.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.